Skip to content
Search

Latest Stories

Report: Usage of more OTC medicines could save NHS £1.7 billion annually

Approximately 25 million GP appointments and 5 million A&E visits are utilised each year for self-treatable illnesses. If these individuals chose to self-treat using over-the-counter (OTC) medications, the potential savings for NHS could amount to at least £1.7 billion annually, according to a research commissioned by Proprietary Association of Great Britain.

The study, conducted by analysts at Frontier Economics, revealed that embracing self-care could bring an additional economic benefit of £350 million annually, as employees would avoid unnecessary time off from work for medical appointments.


Apart from the savings resulting from the increased OTC medicine use, the report emphasises the potential benefits of reclassifying more prescription-only medications (POMs). A mere 5 per cent reduction in NHS prescribing levels and spending could lead to an annual cost-saving of £1.4 billion, encompassing both prescription costs and GP appointments, it said.

“This substantial amount could greatly alleviate financial pressures on the NHS and offer essential resources for recruiting and training much-needed healthcare professionals.”

PAGB, the representative body for OTC medication manufacturers, emphasises the significance of promoting self-care for common ailments and minor injuries.

“Around 92 per cent of the UK population, that’s 61 million people, use OTCs each year to treat self-treatable conditions, saving the NHS vast sums of money and resource,” said Michelle Riddalls, CEO of PAGB. “We know that the NHS is struggling and as this report clearly demonstrates, if policymakers were to truly embrace the opportunities presented by self-care, the NHS could save an additional £3.1 billion. These vast sums could be saved through greater use of existing OTCs (£1.7 billion) combined with further reclassification of prescription-only medicines (£1.4 billion).”

The report underscores the economic and social advantages of OTC medicines. “With an impressive £8.40 return for every £1 spent on OTCs, the ‘well-being savings’ total a substantial £14.9 billion annually.”

According to the report, these savings stem from avoided work absence, totalling £18 billion and £6.4 billion in NHS prescription and appointment cost savings, respectively. “Additionally, consumers enjoy an estimated £15 billion ‘quality of life benefit’ each year, demonstrating the positive impact of self-care and OTC medicine use on overall well-being.”

However, the report acknowledges that the extent of this increase depends on various factors, including demand, unit costs, patient willingness to switch from prescriptions, and changes in prescribing practices.

In 2022, PAGB members manufactured approximately £4.3 billion worth of OTCs in the UK and exported £2.8 billion worth of OTCs worldwide.

Meanwhile, a recent report by Tony Blair Institute proposes facilitating healthcare provision in pharmacies and other spaces to bring services closer to patients and reduce demands on general practice. The paper 'Modern and Sustainable NHS Providing Accessible and Personalised Care for All' outlines six areas for reform, aiming to transform the future of the NHS and improve patient care.

More For You

13 pharmacists achieve RPS core advanced credential with record pass rate

The latest successful cohort includes pharmacists from both England and Scotland.

Pic credit: Getty Images

13 more pharmacists achieve RPS core advanced credential - Highest pass rate yet

The Royal Pharmaceutical Society (RPS) has announced that 13 more pharmacists have successfully completed Core Advanced Credentialling as part of the latest assessment cohort —achieving a remarkable 93% pass rate, the highest to date.

This brings the total number of pharmacists awarded the RPS core advanced credential to 113 since the launch of the Core Advanced Curriculum in 2023, with successful candidates from GP, secondary care and community settings.

Keep ReadingShow less
 Government launches call for evidence on England’s first ever men’s health strategy

Wes Streeting

Pic credit: Getty images

Call for Evidence: Streeting urges public to help shape men’s health strategy

The government is urging men of all ages to come forward and contribute to the development of England’s first-ever men’s health strategy, a key initiative under its Plan for Change.

On Thursday (24), the Department of Health and Social Care (DHSC) launched a 12-week call for evidence, seeking insights from the public, health and social care professionals, academics and employers on ways to prevent and tackle the biggest issues facing men.

Keep ReadingShow less
Slamannan Village Pharmacy sold after 31 years

Slamannan Village Pharmacy

Slamannan Village Pharmacy sold after 31 years

A pharmacy in a small village in Scotland that has served its community for 31 years, has been bought by a group that operates 43 pharmacies across Scotland.

Slamannan Village Pharmacy is heavily relied on by locals sourcing their prescriptions from the village’s sole GP surgery.

Keep ReadingShow less
Kinnock highlights employers’ role in making community pharmacy jobs attractive

The new funding uplift our commitment to rebuilding the sector: Kinnock

Kinnock: ‘Employers have a key role in making community pharmacy jobs attractive’

Health minister Stephen Kinnock has emphasised that employers have a crucial role to play in retaining staff and making careers in community pharmacy more attractive.

His comments came in response to a written question from Victoria Collins MP, the Liberal Democrat spokesperson for science and technology, who asked what steps the Department of Health and Social Care is taking to address staff shortages and prevent the closure of local pharmacies.

Keep ReadingShow less
MHRA approves Pfizer Hympavzi (marstacimab) for haemophilia treatment

Marstacimab is currently being assessed by NICE and the Scottish Medicines Consortium for use on the NHS

gettyimages

Marstacimab approved for haemophilia treatment, Pfizer aims for NHS availability

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Hympavzi(marstacimab) to prevent or reduce bleeding in patients aged 12 years and older, weighing at least 35kg, who have severe haemophilia A or B.

Developed by Pfizer scientists, this groundbreaking treatment is the first of its kind to target a protein involved in the blood clotting process.

Keep ReadingShow less